O	0	8	Combined	Combine	VBN	B-NP
O	9	16	topical	topical	JJ	I-NP
O	17	28	fluconazole	fluconazole	NN	I-NP
O	29	32	and	and	CC	I-NP
O	33	47	corticosteroid	corticosteroid	NN	I-NP
O	48	57	treatment	treatment	NN	I-NP
O	58	61	for	for	IN	B-PP
O	62	74	experimental	experimental	JJ	B-NP
O	75	82	Candida	Candida	NN	I-NP
O	83	91	albicans	albican	NNS	I-NP
O	92	105	keratomycosis	keratomycosis	NN	I-NP
O	105	106	.	.	.	O

O	107	114	PURPOSE	PURPOSE	NN	B-NP
O	114	115	:	:	:	O
O	116	118	To	To	TO	B-VP
O	119	128	determine	determine	VB	I-VP
O	129	132	the	the	DT	B-NP
O	133	137	most	most	RBS	I-NP
O	138	147	efficient	efficient	JJ	I-NP
O	148	152	time	time	NN	I-NP
O	153	158	point	point	NN	I-NP
O	159	162	and	and	CC	O
O	163	176	concentration	concentration	NN	B-NP
O	177	179	of	of	IN	B-PP
O	180	187	topical	topical	JJ	B-NP
O	188	203	corticosteroids	corticosteroid	NNS	I-NP
O	204	206	in	in	IN	B-PP
O	207	214	Candida	Candida	NNP	B-NP
O	215	223	albicans	albicans	NNP	I-NP
O	224	233	keratitis	keratitis	NN	I-NP
O	234	241	treated	treat	VBN	B-VP
O	242	246	with	with	IN	B-PP
O	247	258	fluconazole	fluconazole	NN	B-NP
O	258	259	.	.	.	O

O	260	267	METHODS	METHODS	NNS	B-NP
O	267	268	:	:	:	O
B-Multi-tissue_structure	269	276	Corneas	Cornea	NNS	B-NP
O	277	279	of	of	IN	B-PP
O	280	283	105	105	CD	B-NP
O	284	291	rabbits	rabbit	NNS	I-NP
O	292	296	were	be	VBD	B-VP
O	297	305	infected	infect	VBN	I-VP
O	306	310	with	with	IN	B-PP
O	311	317	viable	viable	JJ	B-NP
O	318	323	yeast	yeast	NN	I-NP
B-Cell	324	329	cells	cell	NNS	I-NP
O	330	332	of	of	IN	B-PP
O	333	334	C	C	NN	B-NP
O	334	335	.	.	.	O
O	336	344	albicans	albican	NNS	B-NP
O	345	346	(	(	(	O
O	346	347	2	2	CD	B-NP
O	347	348	.	.	.	O
O	348	349	5	5	CD	B-NP
O	350	351	x	x	CC	I-NP
O	352	354	10	10	CD	I-NP
O	354	355	(	(	(	O
O	355	356	5	5	CD	B-NP
O	356	357	)	)	)	O
O	357	358	)	)	)	O
O	358	359	.	.	.	O

O	360	365	After	After	IN	B-PP
O	366	367	a	a	DT	B-NP
O	368	370	48	48	CD	I-NP
O	370	371	-	-	HYPH	I-NP
O	371	375	hour	hour	NN	I-NP
O	376	386	incubation	incubation	NN	I-NP
O	387	393	period	period	NN	I-NP
O	393	394	,	,	,	O
O	395	400	seven	seven	CD	B-NP
O	401	407	groups	group	NNS	I-NP
O	408	410	of	of	IN	B-PP
O	411	418	animals	animal	NNS	B-NP
O	419	423	were	be	VBD	B-VP
O	424	431	treated	treat	VBN	I-VP
O	432	435	for	for	IN	B-PP
O	436	438	21	21	CD	B-NP
O	439	443	days	day	NNS	I-NP
O	444	448	with	with	IN	B-PP
O	449	460	fluconazole	fluconazole	NN	B-NP
O	460	461	,	,	,	O
O	462	466	with	with	IN	B-PP
O	467	472	group	group	NN	B-NP
O	473	474	I	I	CD	I-NP
O	475	481	acting	act	VBG	B-VP
O	482	484	as	as	IN	B-PP
O	485	486	a	a	DT	B-NP
O	487	494	control	control	NN	I-NP
O	494	495	,	,	,	O
O	496	499	and	and	CC	O
O	500	506	groups	group	NNS	B-NP
O	507	509	II	II	CD	B-NP
O	510	512	to	to	TO	B-PP
O	513	516	VII	VII	CD	B-NP
O	517	526	receiving	receive	VBG	B-VP
O	527	534	adjunct	adjunct	JJ	B-NP
O	535	542	therapy	therapy	NN	I-NP
O	543	547	with	with	IN	B-PP
O	548	551	the	the	DT	B-NP
O	552	566	corticosteroid	corticosteroid	NN	I-NP
O	567	579	prednisolone	prednisolone	NN	I-NP
O	580	581	(	(	(	O
O	581	582	5	5	CD	B-NP
O	583	585	or	or	CC	I-NP
O	586	588	10	10	CD	I-NP
O	589	594	times	time	NNS	I-NP
O	595	600	daily	daily	RB	I-NP
O	600	601	;	;	:	O
O	602	603	3	3	CD	B-NP
O	603	604	,	,	,	I-NP
O	605	606	9	9	CD	I-NP
O	606	607	,	,	,	O
O	608	610	or	or	CC	O
O	611	613	15	15	CD	B-NP
O	614	618	days	day	NNS	I-NP
O	619	624	after	after	IN	B-PP
O	625	634	infection	infection	NN	B-NP
O	634	635	)	)	)	O
O	635	636	.	.	.	O

O	637	640	The	The	DT	B-NP
O	641	647	degree	degree	NN	I-NP
O	648	650	of	of	IN	B-PP
B-Multi-tissue_structure	651	658	corneal	corneal	JJ	B-NP
O	659	671	infiltration	infiltration	NN	I-NP
O	671	672	,	,	,	O
O	673	683	ulceration	ulceration	NN	B-NP
O	683	684	,	,	,	O
B-Multi-tissue_structure	685	692	corneal	corneal	JJ	B-NP
O	693	701	clouding	clouding	NN	I-NP
O	701	702	,	,	,	O
O	703	711	hypopyon	hypopyon	NN	B-NP
O	711	712	,	,	,	O
O	713	727	conjunctivitis	conjunctivitis	NN	B-NP
O	727	728	,	,	,	O
O	729	747	neovascularization	neovascularization	NN	B-NP
O	747	748	,	,	,	O
O	749	752	and	and	CC	O
B-Multi-tissue_structure	753	760	corneal	corneal	JJ	B-NP
O	761	772	perforation	perforation	NN	I-NP
O	773	776	was	be	VBD	B-VP
O	777	786	monitored	monitor	VBN	I-VP
O	787	791	over	over	IN	B-PP
O	792	793	a	a	DT	B-NP
O	794	796	24	24	CD	I-NP
O	796	797	-	-	HYPH	I-NP
O	797	800	day	day	NN	I-NP
O	801	807	period	period	NN	I-NP
O	807	808	,	,	,	O
O	809	811	as	as	RB	B-CONJP
O	812	816	well	well	RB	I-CONJP
O	817	819	as	as	IN	I-CONJP
O	820	833	recultivation	recultivation	NN	B-NP
O	834	837	and	and	CC	I-NP
O	838	848	resistance	resistance	NN	I-NP
O	849	851	to	to	TO	B-PP
O	852	863	fluconazole	fluconazole	NN	B-NP
O	864	866	of	of	IN	B-PP
O	867	870	the	the	DT	B-NP
O	871	872	C	C	NN	I-NP
O	872	873	.	.	.	O
O	874	882	albicans	albican	NNS	B-NP
O	883	891	pathogen	pathogen	NN	I-NP
O	891	892	.	.	.	O

O	893	900	RESULTS	RESULTS	NNS	B-NP
O	900	901	:	:	:	O
O	902	905	The	The	DT	B-NP
O	906	913	control	control	NN	I-NP
O	914	919	group	group	NN	I-NP
O	920	926	showed	show	VBD	B-VP
O	927	930	the	the	DT	B-NP
O	931	938	highest	high	JJS	I-NP
O	939	944	level	level	NN	I-NP
O	945	947	of	of	IN	B-PP
B-Multi-tissue_structure	948	955	corneal	corneal	JJ	B-NP
O	956	964	clouding	clouding	NN	I-NP
O	965	968	and	and	CC	I-NP
O	969	987	neovascularization	neovascularization	NN	I-NP
O	987	988	.	.	.	O

O	989	991	In	In	IN	B-PP
O	992	1002	comparison	comparison	NN	B-NP
O	1002	1003	,	,	,	O
O	1004	1006	by	by	IN	B-PP
O	1007	1010	day	day	NN	B-NP
O	1011	1013	24	24	CD	I-NP
O	1013	1014	,	,	,	O
O	1015	1018	the	the	DT	B-NP
O	1019	1027	majority	majority	NN	I-NP
O	1028	1030	of	of	IN	B-PP
O	1031	1037	groups	group	NNS	B-NP
O	1038	1042	also	also	RB	B-VP
O	1043	1050	treated	treat	VBN	I-VP
O	1051	1055	with	with	IN	B-PP
O	1056	1068	prednisolone	prednisolone	NN	B-NP
O	1069	1078	displayed	display	VBD	B-VP
O	1079	1092	significantly	significantly	RB	B-NP
O	1093	1097	less	less	RBR	I-NP
B-Multi-tissue_structure	1098	1105	corneal	corneal	JJ	I-NP
O	1106	1114	clouding	clouding	NN	I-NP
O	1115	1118	and	and	CC	I-NP
O	1119	1137	neovascularization	neovascularization	NN	I-NP
O	1137	1138	.	.	.	O

O	1139	1141	An	An	DT	B-NP
O	1142	1151	immediate	immediate	JJ	I-NP
O	1152	1160	decrease	decrease	NN	I-NP
O	1161	1163	in	in	IN	B-PP
B-Multi-tissue_structure	1164	1171	corneal	corneal	JJ	B-NP
O	1172	1180	clouding	clouding	NN	I-NP
O	1181	1184	was	be	VBD	B-VP
O	1185	1193	observed	observe	VBN	I-VP
O	1194	1196	in	in	IN	B-PP
O	1197	1203	groups	group	NNS	B-NP
O	1204	1211	treated	treat	VBN	B-VP
O	1212	1216	with	with	IN	B-PP
O	1217	1227	additional	additional	JJ	B-NP
O	1228	1231	low	low	JJ	I-NP
O	1231	1232	-	-	HYPH	I-NP
O	1233	1235	or	or	CC	I-NP
O	1236	1240	high	high	JJ	I-NP
O	1240	1241	-	-	HYPH	I-NP
O	1241	1245	dose	dose	NN	I-NP
O	1246	1258	prednisolone	prednisolone	NN	I-NP
O	1259	1263	from	from	IN	B-PP
O	1264	1267	day	day	NN	B-NP
O	1268	1269	9	9	CD	I-NP
O	1270	1275	after	after	IN	B-PP
O	1276	1287	inoculation	inoculation	NN	B-NP
O	1287	1288	.	.	.	O

O	1289	1294	After	After	IN	B-PP
O	1295	1305	additional	additional	JJ	B-NP
O	1306	1318	prednisolone	prednisolone	NN	I-NP
O	1319	1328	treatment	treatment	NN	I-NP
O	1329	1333	from	from	IN	B-PP
O	1334	1337	day	day	NN	B-NP
O	1338	1339	9	9	CD	I-NP
O	1340	1342	or	or	CC	I-NP
O	1343	1345	15	15	CD	I-NP
O	1346	1351	after	after	IN	B-PP
O	1352	1363	inoculation	inoculation	NN	B-NP
O	1363	1364	,	,	,	O
O	1365	1367	no	no	DT	B-NP
O	1368	1379	significant	significant	JJ	I-NP
O	1380	1390	difference	difference	NN	I-NP
O	1391	1394	was	be	VBD	B-VP
O	1395	1403	detected	detect	VBN	I-VP
O	1404	1406	in	in	IN	B-PP
O	1407	1410	the	the	DT	B-NP
O	1411	1424	recultivation	recultivation	NN	I-NP
O	1425	1429	rate	rate	NN	I-NP
O	1430	1432	of	of	IN	B-PP
O	1433	1434	C	C	NN	B-NP
O	1434	1435	.	.	.	O
O	1436	1444	albicans	albican	NNS	B-NP
O	1445	1453	compared	compare	VBN	B-PP
O	1454	1458	with	with	IN	B-PP
O	1459	1462	the	the	DT	B-NP
O	1463	1470	control	control	NN	I-NP
O	1470	1471	.	.	.	O

O	1472	1477	Early	Early	RB	B-NP
O	1478	1492	administration	administration	NN	I-NP
O	1493	1495	of	of	IN	B-PP
O	1496	1508	prednisolone	prednisolone	NN	B-NP
O	1509	1510	(	(	(	O
O	1510	1513	day	day	NN	B-NP
O	1514	1515	3	3	CD	I-NP
O	1515	1516	,	,	,	O
O	1517	1520	low	low	JJ	B-NP
O	1521	1524	and	and	CC	I-NP
O	1525	1529	high	high	JJ	I-NP
O	1530	1534	dose	dose	NN	I-NP
O	1534	1535	)	)	)	O
O	1536	1544	resulted	result	VBD	B-VP
O	1545	1547	in	in	IN	B-PP
O	1548	1551	the	the	DT	B-NP
O	1552	1565	recultivation	recultivation	NN	I-NP
O	1566	1568	of	of	IN	B-PP
O	1569	1582	significantly	significantly	RB	B-NP
O	1583	1587	more	more	JJR	I-NP
O	1588	1589	C	C	NN	I-NP
O	1589	1590	.	.	.	I-NP
O	1591	1599	albicans	albican	NNS	I-NP
O	1599	1600	.	.	.	O

O	1601	1612	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1612	1613	:	:	:	O
O	1614	1625	Fluconazole	Fluconazole	NN	B-NP
O	1626	1630	plus	plus	CC	O
O	1631	1638	adjunct	adjunct	JJ	B-NP
O	1639	1643	high	high	JJ	I-NP
O	1643	1644	-	-	HYPH	I-NP
O	1644	1648	dose	dose	NN	I-NP
O	1649	1661	prednisolone	prednisolone	NN	I-NP
O	1662	1671	treatment	treatment	NN	I-NP
O	1672	1675	was	be	VBD	B-VP
O	1676	1680	most	most	RBS	B-ADJP
O	1681	1690	effective	effective	JJ	I-ADJP
O	1691	1695	when	when	WRB	B-ADVP
O	1696	1708	administered	administer	VBN	B-VP
O	1709	1710	9	9	CD	B-NP
O	1711	1715	days	day	NNS	I-NP
O	1716	1721	after	after	IN	B-PP
O	1722	1731	infection	infection	NN	B-NP
O	1731	1732	.	.	.	O

O	1733	1736	The	The	DT	B-NP
O	1737	1744	delayed	delay	VBN	I-NP
O	1745	1756	application	application	NN	I-NP
O	1757	1759	of	of	IN	B-PP
O	1760	1775	corticosteroids	corticosteroid	NNS	B-NP
O	1776	1781	after	after	IN	B-PP
O	1782	1791	treatment	treatment	NN	B-NP
O	1792	1796	with	with	IN	B-PP
O	1797	1808	antimycotic	antimycotic	JJ	B-NP
O	1809	1814	drugs	drug	NNS	I-NP
O	1815	1817	in	in	IN	B-PP
O	1818	1823	cases	case	NNS	B-NP
O	1824	1826	of	of	IN	B-PP
O	1827	1833	fungal	fungal	JJ	B-NP
O	1834	1843	keratitis	keratitis	NN	I-NP
O	1844	1846	is	be	VBZ	B-VP
O	1847	1856	therefore	therefore	RB	I-VP
O	1857	1860	not	not	RB	I-VP
O	1861	1876	contraindicated	contraindicate	VBN	I-VP
O	1877	1880	and	and	CC	O
O	1881	1884	may	may	MD	B-VP
O	1885	1887	be	be	VB	I-VP
O	1888	1898	beneficial	beneficial	JJ	B-ADJP
O	1899	1901	in	in	IN	B-PP
O	1902	1910	patients	patient	NNS	B-NP
O	1910	1911	.	.	.	O

